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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2016, Taiwan P
NC-ND license (http://creativecommoBackground: To analyze the correlation of cytokines with clinical inflammatory indexes in sys-
temic onset juvenile idiopathic arthritis (SOJIA).
Methods: A total of 30 active SOJIAs, 30 remission SOJIAs, and 20 normal controls were
enrolled. The clinical inflammatory indexes such as tender joints counts, swelling joints
counts, C-reactive protein, erythrocyte sedimentation rate, visual analogue scale (VAS), and
disease activity score 28 (DAS28) were detected. The serum cytokines interleukin (IL)-17, IL-
6, IL-21, interferon (IFN)-g, and IL-4 levels were determined with enzyme-linked immunosor-
bent assay method. The correlation coefficients between these cytokines and two clinical in-
dexes (VAS and DAS28) in the active SOJIA group were calculated with the Spearman’s method.
Results: The serum IL-17 and IL-6 levels in active SOJIA group were significantly increased
compared with those in the remission SOJIA group and control group (p < 0.05), and the serum
IL-21, IFN-g, and IL-4 levels showed no obvious difference. In the active SOJIA group, the
Spearman coefficients between IL-17 and DAS28, IL-17 and IL-6, IL-6 and DAS28, and between
IL-17 and VAS were 0.686 (p Z 0.000), 0.833 (p Z 0.000), 0.633 (p Z 0.000), and 0.524
(p Z 0.003), respectively. There was no correlation between cytokines of IL-21, IFN-g, and
IL-4 and the clinical indexes of DAS28 and VAS. Furthermore, in the other two groups, none
of the five cytokines exhibited an association with DAS28 or VAS.
Conclusion: IL-6 and IL-17 were significantly correlated with DAS28 and VAS, and they might be
considered as therapeutic targets for the treatment of SOJIA.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).of Pediatrics, Renji Hospital, School of Medicine, Shanghai Jiao Tong University ,145 Shandongzhong
com (L.-F. Cao).
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ediatric Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-
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Systemic onset juvenile idiopathic arthritis (SOJIA) is a rare
inflammatory disorder disease and the symptoms of SOJIA
may be accompanied by evanescent rashes, lymph node
enlargement, hepatomegaly, splenomegaly, or serositis.1,2
SOJIA accounts for 5e10% of deaths from JIA, which is an
important cause of short- and long-term disability.3,4
Moreover, macrophage activation syndrome is a poten-
tially fatal complication of SOJIA.5 It is therefore important
to study the pathogenesis of SOJIA further.
Cytokines play an important role in the pathogenesis of
SOJIA. Pascual et al6 have reported that interleukin (IL)-1
contributes to the development of SOJIA through the
mediation of the inflammatory cascade. Other cytokines,
such as IL-10, IL-1b, IL-6, IL-17, and tumor necrosis factor
alpha (TNFa), participate and play crucial roles in the
development of JIA, SOJIA, or rheumatoid arthritis
(RA).7e11 IL-21, similar to IL-6, together with transforming
growth factor b could induce the differentiation of
Th17 cells, which secrete IL-17, IL-22, and IL-21.12 The
Th17 cells belong to the CD4þ T cells that produce IL-17.13
Our previous findings that Th17 cell abundance was asso-
ciated with the SOJIA activity confirmed the involvement of
Th17 in the pathogenesis of SOJIA. High levels of IL-17 were
commonly discovered in RA patients and it was confirmed
that IL-17 played a significant role in the pathogenesis of RA
via the contribution to inflammatory process.14,15 In addi-
tion, other cytokines which are secreted by the Th-cell
subsets also play significant roles in the inflammation pro-
cess. For instance, interferon (IFN)-g and IL-4 participate in
the development or differentiation of Th1 cells and Th2
cells, respectively, acting as regulators of immune re-
sponses and inflammatory diseases.16,17 Although the cy-
tokines including IL-17, IL-6, IL-21, IFN-g, and IL-4 are
implicated in the development of arthritis or inflammatory
diseases, studies rarely reported their roles in the devel-
opment of SOJIA. Thus, our research explored the effects of
these five cytokines on the pathogenesis of SOJIA, and
examined whether these cytokines would exert a proin-
flammatory function during this regulation.
In our study, the clinical inflammatory indexes, such as
tender joints counts (TJC), swelling joints counts (SJC), C-
reactive protein (CRP), erythrocyte sedimentation rate
(ESR), visual analogue scale (VAS), and disease activity
score 28 (DAS28) were detected, and the expression levels
of serum IL-17, IL-6, IL-21, IFN-g, and IL-4 in patients with
SOJIA were determined in order to analyze the correlations
among them. We also analyzed the correlation between the
five cytokines and the clinical inflammatory indexes.
2. Methods
2.1. Patients
This study was approved by the ethics committee of Renji
Hospital, School of Medicine, Shanghai Jiaotong University.
All patients were diagnosed with SOJIA based on the In-
ternational League of Associations for Rheumatology clas-
sification.18,19 SOJIA patients enrolled in this study had had
no infectious diseases for at least 2 weeks prior to thediagnosis. Patients fulfilling the following criteria were
excluded from this study: (1) the patients or their imme-
diate family had a history of psoriasis; (2) the patients were
boys over 6 years old with HLA-B27 arthritis; (3) the pa-
tients or their immediate family were or had been diag-
nosed with ankylosing spondylitis, inflammation arthritis
related to attachment points, acute anterior uveitis, in-
flammatory bowel disease, or Reiter’s syndrome; and (4)
the patients tested positive for rheumatoid factors twice
within a period of 3 months.
SOJIA patients were divided into two groups: the active
SOJIA group and the remission SOJIA group. Active SOJIA
patients were diagnosed as follows: (1) suffering from fe-
vers more than twice in one day and arthritis occurring in
more than two joints; (2) serum CRP
concentration  30 mg/L; and (3) serum glucocorticoids
dosage  1 mg/kg/d. Remission SOJIA patients were diag-
nosed as follows: (1) no fever and the arthritis occurring on
one or no joints; (2) serum CRP concentration < 30 mg/L;
and (3) serum glucocorticoids dosage < 1 mg/kg/d. Thus,
60 SOJIA patients (n Z 30 for each group) were enrolled
from January 2012 to December 2013.
Normal healthy children were enrolled as the control
group (n Z 20). All 60 SOJIA patients accepted the con-
ventional treatments in our hospital during their illness.
Fasting vein blood (2 mL) was obtained before breakfast.
Written informed consent was obtained from every partic-
ipant’s parents or other guardians.
2.2. SOJIA disease assessment
The SOJIA clinical inflammatory indexes (TJC, SJC, CRP,
ESR, VAS, and DAS28) were constructed based on the
American College of Rheumatology and European League of
Associations for Rheumatology guideline.20 Pain index was
evaluated with VAS from 0 (no pain) to 10 (unbearable
pain).21
DAS28 is a well-established evaluation system to define
remission in RA.22 To assess the criteria for remission based
on DAS28 and to compare disease activity and improve-
ment, DAS28 was calculated based on the formula
described in Fransen’s study.23 Based on DAS28 score, SOJIA
disease activity was classified into five grades: remission
(DAS28  2.6), low activity (2.6 < DAS28  3.2), moderate
activity (3.2 < DAS28  5.1), and high activity
(DAS28 > 5.1).
2.3. Evaluation of the serum IL-17, IL-6, IL-21, IFN-
g, and IL-4 levels
Two milliliters of venous blood was obtained from all pa-
tients and centrifuged at 1500 r/min for 10 minutes. The
supernatant was used to measure the expression levels of
serum IL-17, IL-6, IL-21, IFN-g, and IL-4 using enzyme-
linked immunosorbent assay kits (ShangHai Sunteam
Biotech Co Ltd.) following the manufactures’ instructions.
2.4. Statistical analysis
Quantitative data were calculated by mean  standard
error of the mean. Statistical analysis was carried out using
Table 1 The basic characteristics and clinical data of patients in active systemic onset juvenile idiopathic arthritis patients
group, remission systemic onset juvenile idiopathic arthritis group, and normal controls.
Item Active Remission Control
No. of patients 30 30 20
Sex ratio (male: female) 19:11 16:14 10:10
Age (yr), (mean, range) 7.9  4.2 (4.5e16.2) 6.2  3.8 (3.0e14.8) 5.8  2.9 (3.8e16.0)
Duration (mo) (mean, range) 28.2  18.5 (5e64) 34.0  20.1 (8e84) e
TJC (mean, range) 3  0.8 (0e6)* 0.5  0.3 (0e2) e
SJC (mean, range) 3  1.9 (0e6)* 0.5  0.4 (0e2) e
VAS (mean, range) 40  15.2 (0e80)* 10  3.6 (0e20) e
CRP (mean, range) 58.3  19.5 (30e220)* 6.4  3.1 (3.16e22.5) 5.59  2.0 (3.16e10)
ESR (mean, range) 53.1  23.1 (10e120)* 12.3  5.4 (2e30) 8.95  4.5 (0e20)
DAS28 (mean, range) 3.46  0.7 (2.6e4.5)* 1.83  0.2 (1.5e2.9) e
Active Z active systemic onset juvenile idiopathic arthritis patients; Control Z normal control group; CRP Z C-reactive protein;
DAS28 Z disease activity score 28; ESR Z erythrocyte sedimentation rate; SJC Z swelling joints counts; Remission Z Remission
systemic onset juvenile idiopathic arthritis patients; TJC Z tender joints counts; VAS Z visual analogue scale.
* Indicates significant differences among groups.
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analysis of variance (ANOVA) test was compared among
groups. Pearson’s correlation coefficient was used to
analyze the correlation. Spearman’s correlation coefficient
was used for comparing categorical variables. A p value
<0.05 was chosen as cut-off criterion.
3. Results
3.1. Characteristics of the patients and controls
The basic characteristics of these patients or controls are
shown in Table 1. The sex ratios (male:female) in the active
SOJIA group, remission SOJIA group, and controls were
19:11, 16:14, and 10:10, respectively. The average ages of
the three groups were 7.9  4.2 years (range:
4.5e16.2 years), 6.2  3.8 years (range: 3.0e14.8 years),
and 5.8  2.9 years (range: 3.8e16.0 years), respectively.
The duration of SOJIA disease in the active SOJIA group and
the remission SOJIA group were 28.2  18.5 months (range:
5e64 months) and 34.0  20.1 months (range:
8e84 months), respectively (Table 1).
3.2. SOJIA disease assessment
The SOJIA disease assessment indicators (TJC, SJC, CRP,
ESR, VAS, and DAS28) were evaluated (Table 1). The levelsTable 2 Evaluation of the expression levels of interleukin (IL)-
onset juvenile idiopathic arthritis group, remission systemic onset
Groups IL-17 (pg/mL) IL-6 (pg/mL)
Active 131.07  56.28*,y 1567.23  1284.19*,y
Remission 58.40  29.82 1125.26  504.93*
Control 50.01  18.36 159.33  35.62
p F Z 33.88
0.000
F Z 7.33
0.001
* p < 0.05 compared with normal control group.
y p < 0.05 compared with remission SOJIA group.of TJC and SJC were very similar, and significant difference
was found between the active SOJIA group and the remis-
sion SOJIA group (p < 0.05). VAS and DAS28 in the active
SOJIA group were significantly higher than those in the
remission SOJIA group (p < 0.05). CRP and ESR in the active
SOJIA group were significantly higher than those in the
remission SOJIA group and the control group (p < 0.05;
Table 1).3.3. Evaluation of the serum IL-17, IL-6, IL-21, IFN-
g, and IL-4 levels
The serum IL-17, IL-6, IL-21, IFN-g, and IL-4 expression
levels were determined using enzyme-linked immunosor-
bent assay (Table 2). One-way ANOVA indicated that pro-
nounced differences of the IL-17 expression levels in three
groups were observed (F Z 33.88, p Z 0.000). Further-
more, the comparison between any two groups revealed
that the IL-17 level in the active SOJIA group was signifi-
cantly higher than the other groups (p < 0.05), while sig-
nificant differences were not detected between the
remission SOJIA group and control group (p > 0.05).
Likewise, the IL-6 levels in the three groups were
also significantly different (F Z 7.33, p Z 0.001). By
the comparison between any two groups, the active SOJIA
group showed a markedly higher IL-6 level than the
other two groups, and notably the remission SOJIA group17, IL-6, IL-21, interferon-g, and IL-4 in the active systemic
juvenile idiopathic arthritis group, and normal control group.
IL-21 (pg/mL) IFN-g (pg/mL) IL-4 (pg/mL)
116.70  72.49* 33.32  28.06 65.03  23.67
98.63  67.79 20.57  13.02 61.81  28.22
78.30  51.58 17.24  25.48 59.12  25.48
F Z 2.04
0.136
F Z 2.54
0.089
F Z 0.27
0.761
The effect of IL-6 and IL-17 on SOJIA 399also presented a higher IL-6 level than control group
(p < 0.05).
One-way ANOVA revealed no significantly different IL-21
levels among the three groups (F Z 2.04, p Z 0.136).
However, comparison between any two groups showed that
IL-21 in the active SOJIA group was slightly higher than in
the controls (p < 0.05; Table 2).
No significantly different levels of IFN-g and IL-4 were
observed among the three groups (IFN-g: F Z 2.54,
p Z 0.089; IL-4: F Z 0.27, p Z 0.761; Table 2).3.4. Correlation analysis of cytokines and clinical
index in active SOJIA group
In the active SOJIA group, Spearman coefficients suggested
a significant positive correlation between the expression
level of IL-17 and DAS28 (rZ 0.686, pZ 0.000; Figure 1A);
the IL-17 level was also positively associated with IL-6 levelFigure 1 The correlation analysis of the expression levels of cyto
disease activity score 28 (DAS28) and visual analogue scale in activ
correlation between the expression level of IL-17 and DAS28 (r Z
levels of IL-17 and IL-6 levels (rZ 0.833, pZ 0.000); (C) the correla
p Z 0.000); (D) the correlation between the expression level o
DAS28 Z disease activity score 28; IL Z interleukin; VAS Z visualwith significance (r Z 0.833, p Z 0.000; Figure 1B); and
significant positive association between IL-6 level and
DAS28, was detected (r Z 0.633, p Z 0.000, Figure 1C). In
addition, IL-17 level was positively correlated with VAS with
significance (r Z 0.524, p Z 0.003, Figure 1D). However,
the remaining three cytokines did not show any correlations
with either DAS28 or VAS in this group.
In the other two groups, none of the five cytokines
exhibited an association with DAS28 or VAS.4. Discussion
In this study, the expression levels of serum IL-17 and IL-6 in
the active SOJIA group were significantly increased
compared with those in the remission SOJIA group and
control group, while no obviously different levels of serum
IL-21, IFN-g, and IL-4 were discovered among the three
groups. Moreover, the expression level of IL-21 in the activekines of interleukin (IL)-17 and IL-6 and the clinical indexes of
e systemic onset juvenile idiopathic arthritis patients: (A) the
0.686, p Z 0.000); (B) the correlation between the expression
tion between the expression level of IL-6 and DAS28 (rZ 0.633,
f IL-17 and visual analogue scale (r Z 0.524, p Z 0.003).
analogue scale.
400 L.-Y. Xu et alSOJIA group was also significantly higher than in the control
group. These results implied that IL-17 and IL-6 might
contribute to the pathogenesis of SOJIA.
IL-6 is a pleiotropic cytokine with a wide range of bio-
logical activities in the regulation of immunity, inflamma-
tion, and oncogenesis, and the high level IL-6 has been
detected in some inflammatory diseases such as JIA and RA,
suggesting that the overexpression of IL-6 contributes
greatly to the pathogenesis of these diseases.8,9,24,25 IL-6 is
indispensable for the induction of Th17, which is involved in
the pathogenesis of these inflammatory diseases, via the
Janus family tyrosine kinaseesignal transducer and acti-
vator of transcription and the Ras-mitogen-activated pro-
tein kinase pathways.25e28 However, a humanized anti-IL-
6R (IL-6 receptor) antibody, which decreased the produc-
tion of IL-6R, has been considered to be a new therapeutic
approach for RA and systemic JIA.25 Furthermore, IL-6 is
proposed as a therapeutic target in SOJIA and other
intractable diseases, possibly through prevention of pro-
gression to macrophage activation syndrome.29
In the present study, the expression levels serum IL-17
and IL-6 in the active SOJIA group were significantly higher
than those in the remission SOJIA group and the control
group. In the active SOJIA group, significant positive asso-
ciations between two cytokines of IL-17 and IL-6 and the
clinical index DAS28 were detected. Additionally, IL-17 was
positively correlated with IL-6 with statistical significance
in this group. DAS28 is usually used to define remission RA or
evaluate SOJIA disease activity.22,23 The close relationships
between the two cytokines and DAS28 indicated that IL-17
and IL-6 could serve as two indicators of SOJIA disease ac-
tivity. Moreover, IL-17 is secreted by Th17 cells which in-
fluence the pathogenesis of autoimmune diseases,12,30 and
it contributes to the pathogenesis of RA by enhancing the
production of IL-6 and IL-8.31,32 In addition, Fischer et al33
reported that combined inhibition of TNFa and IL-17 had
a synergistic effect in suppression of human mesenchymal
cells and that bispecific anti-TNFa/IL-17 antibodies could
be used for the treatment of arthritis.33 These results
collectively implied that both IL-17 and IL-6 might
contribute to the development of SOJIA, and they might be
considered as the therapeutic targets for the treatment of
SOJIA.
Ma et al34 demonstrated that IL-17 might contribute to
the balance of Th1/Th2 cells through the detection of IFN-g
and IL-4 expression, secreted by Th1 cells and Th2 cells,
respectively.34 Furthermore, IL-21, similar to IL-6, together
with transforming growth factor-b could induce the differ-
entiation of Th17 cells, independently of the effect of IL-
6.35 IL-6 could indirectly induce the production of IL-21 by
activating CD4 cells.36 The blockade of IL-6R was accom-
panied by the decrease of IL-21 production.37 However, the
expression of IL-21, IFN-g, and IL-4 showed nonsignificant
higher levels in the active SOJIA group compared with those
in the other groups.
One limitation to our research was the lack of a statis-
tical study on the changes of the expression levels of those
cytokines during the illness treatments. This might be the
reason for the conclusion that there were no correlations
between cytokines and the clinical indexes of DAS28 or VAS.
Based on these results, we speculated that IL-21, IFN-g,
and IL-4 might not be involved in the development of SOJIA.Therefore, further verification experiments are needed not
only to confirm the speculations above, but also to ascer-
tain the treatment for SOJIA.
5. Conclusion
Cytokines IL-17 and IL-6 were closely associated with the
clinical inflammatory indexes and they might be used as
therapeutic targets for the treatment of SOJIA.
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